Omilancor

Omilancor (BT-11) is an experimental drug which acts as an activator of the protein Lanthionine Synthetase C-like 2 (LANCL2). It has antiinflammatory effects and shows efficacy against psoriasis as well as inflammatory bowel conditions, and is in clinical trials for the treatment of Crohn's disease and ulcerative colitis.[1][2][3] It also shows affinity for the enzyme MAP2K6 and may have potential application in the treatment of intervertebral disc degeneration.[4]

## References

1. ↑ "First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis". Scientific Reports 11 (1): 19827. October 2021. doi:10.1038/s41598-021-99349-y. PMID 34615968. Bibcode: 2021NatSR..1119827T.
2. ↑ "Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation". Inflammatory Bowel Diseases 30 (1): 103–113. January 2024. doi:10.1093/ibd/izad124. PMID 37436905.
3. ↑ "Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease". Inflammatory Bowel Diseases 30 (4): 671–680. April 2024. doi:10.1093/ibd/izad258. PMID 37934790.
4. ↑ "Omilancor mitigates the senescence of nucleus pulposus cells induced by DDP through targeting MAP2K6". Aging 16 (6): 5050–5064. March 2024. doi:10.18632/aging.205588. PMID 38517363.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Omilancor. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Omilancor&oldid=4037358"